ENGRAIL THERAPEUTICS
Engrail is forging a new direction to reduce the enormous burden of diseases that impact the nervous system. We unite biological insights with clinically meaningful solutions to build and catalyze a diversified portfolio of transformative medicines. Harnessing our rigorous scientific approach to identify the most promising therapies, we leverage our flexible transaction model to advance assets with validated mechanisms and efficiently move them through development to commercialization.
ENGRAIL THERAPEUTICS
Industry:
Health Care Life Science Medical Pharmaceutical
Founded:
2019-01-01
Address:
San Diego, California, United States
Country:
United States
Website Url:
http://www.engrail.com
Total Employee:
1+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
64 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress
Similar Organizations
Autobahn Therapeutics
Autobahn Therapeutics is a developer of regenerative medicines to restore hope for people affected by CNS disorders.
Dyne Therapeutics
Dyne Therapeutics is a developer of targeted therapies intended for serious muscle diseases.
Minute Molecular Diagnostics
Minute Molecular Diagnostics is a developer of a molecular diagnostics device designed to provide rapid immunoassays.
Neuron23
Neuron23 is a developer of drugs intended to treat Parkinson's disease and Alzheimer's disease.
Current Advisors List
Current Employees Featured
Founder
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2021-02-02 | Neurocycle Therapeutics | Neurocycle Therapeutics acquired by Engrail Therapeutics | N/A |
Investors List
Nan Fung Life Sciences
Nan Fung Life Sciences investment in Series A - Engrail Therapeutics
Nan Fung Life Sciences
Nan Fung Life Sciences investment in Series A - Engrail Therapeutics
Official Site Inspections
http://www.engrail.com Semrush global rank: 5.69 M Semrush visits lastest month: 1.48 K
- Host name: 162.60.66.34.bc.googleusercontent.com
- IP address: 34.66.60.162
- Location: United States
- Latitude: 38.6583
- Longitude: -77.2481
- Timezone: America/New_York
More informations about "Engrail Therapeutics"
About Us | Engrail
Prior to cofounding Engrail Therapeutics, Stephen gained broad portfolio experience at Zeneca and AstraZeneca. After 12 years at Zeneca/AstraZeneca, he spent 13 years at Novartis in the …See details»
Engrail Therapeutics - Crunchbase Company Profile
Organization. Engrail Therapeutics . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. About. Engrail Therapeutics is a developer of medicines to transform the lives of …See details»
Engrail Therapeutics Announces Positive Results of …
Jun 7, 2022 Vikram Sudarsan, Ph.D., chief executive officer and president of Engrail added, “the positive ENX-101 phase 1b clinical results are just one of many important outcomes we expect to see from the organization over the …See details»
Engrail Therapeutics - LinkedIn
Engrail Therapeutics | 3,791 followers on LinkedIn. Transforming the lives of patients with life-limiting diseases of the nervous system | We are a neuroscience company forging a new direction to ...See details»
Engrail Therapeutics Company Profile 2024: Valuation, …
Engrail Therapeutics is headquartered in San Diego, CA. What is the size of Engrail Therapeutics? Engrail Therapeutics has 31 total employees. What industry is Engrail Therapeutics in? Engrail Therapeutics’s primary industry is …See details»
Engrail Therapeutics Initiates the ENCALM Phase 2
Jul 18, 2023 Engrail Therapeutics is a clinical-stage pharmaceutical company founded in 2019 with the aspiration of becoming a leader in neuroscience. We are committed to rapidly advancing our innovative ...See details»
Engrail Therapeutics Announces Positive Results of …
Jun 7, 2022 Vikram Sudarsan, Ph.D., chief executive officer and president of Engrail added, “the positive ENX-101 phase 1b clinical results are just one of many important outcomes we expect to see from the ...See details»
Engrail Therapeutics Closes Oversubscribed $157M Series B …
Mar 20, 2024 Engrail Therapeuticsâ„¢ (Engrail) (the Company), a precision neuroscience company focused on the development of transformational therapies to improve the lives of …See details»
Investors & Media - Engrail Precision Neuroscience
INVESTORS Engrail is a clinical-stage pharmaceutical company with a rich pipeline of precision-targeted neuroscience programs designed to improve the lives of patients with …See details»
Engrail Therapeutics: Addressing the Need for Safer, …
May 23, 2024 Q&A with Vikram Sudarsan, founder and CEO of Engrail Therapeutics ST. LOUIS, MO (May 23, 2024) — Anxiety is a mental health problem of epic proportions, affecting more than 300 million people ...See details»
Engrail Therapeutics Closes Oversubscribed $157M Series B …
SAN DIEGO, March 19, 2024--Engrail Therapeuticsâ„¢ (Engrail) (the Company), a precision neuroscience company focused on the development of transformational therapies to improve …See details»
Engrail Therapeutics and The Texas A&M University System Enter ...
Sep 8, 2021 Engrail Therapeuticsâ„¢ (Engrail) (the Company), a neuroscience company focused on the acquisition, development and commercialization of patient-centric ... Our organization …See details»
ENX-104 - Drug Targets, Indications, Patents - Synapse
The first-in-human Phase 1 clinical study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamic profile of ENX-104 in healthy volunteers SAN DIEGO, Sept. 18, 2024 …See details»
Engrail Therapeutics Closes Oversubscribed $157M Series B …
SAN DIEGO – March 19, 2024 – Engrail Therapeuticsâ„¢ (Engrail) (the Company), a precision neuroscience company focused on the development of transformational therapies to improve …See details»
Engrail Therapeutics: Addressing the Need for Safer, More …
May 22, 2024 Anxiety is a mental health problem of epic proportions, affecting more than 300 million people worldwide, according to the World Health Organization (WHO). “The numbers …See details»
ENX-102 in Generalized Anxiety Disorder - ICH GCP
Feb 18, 2023 August 29, 2024 updated by: Engrail Therapeutics INC. The ENCALM Trial: a Randomized, Double-blind, Placebo-controlled Monotherapy Trial to Evaluate the Efficacy and …See details»
Engrail Therapeutics Initiates the ENCALM Phase 2 Clinical Trial of …
Jul 18, 2023 SAN DIEGO–(BUSINESS WIRE)–Engrail Therapeuticsâ„¢ (Engrail) (the Company), a precision neuroscience company focused on the acquisition, development, and …See details»
ENX-102 - Drug Targets, Indications, Patents - Synapse - Patsnap
Nov 21, 2024 The first-in-human Phase 1 clinical study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamic profile of ENX-104 in healthy volunteers SAN …See details»
Engrail Therapeutics Closes Oversubscribed $157M Series B …
SAN DIEGO, March 20, 2024 /PRNewswire/ -- Engrail Therapeuticsâ„¢ (Engrail) (the Company), a precision neuroscience company focused on the development of transformational therapies to …See details»